Modality
ADC
MOA
BCL-2i
Target
CD38
Pathway
Innate Imm
SCD
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
Phase 1Current
NCT06259974
110 pts·SCD
2021-12→TBD·Completed
110 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06259974 | Phase 1 | SCD | Completed | 110 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Tezecilimab | Takeda | NDA/BLA | Tau |